Lemaitre Vascular (LMAT) Misses Q4 EPS by 3c

Lemaitre Vascular (NASDAQ: LMAT) reported Q4 EPS of $0.28, $0.03 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $39.5 million versus the consensus estimate of $39.7 million.

GUIDANCE:

Lemaitre Vascular sees Q1 2022 EPS of $0.26-$0.30, versus the consensus of $0.30. Lemaitre Vascular sees Q1 2022 revenue of $37.7-39.7 million, versus the consensus of $39.22 million.

Lemaitre Vascular sees FY2022 EPS of $1.35-$1.45, versus the consensus of $1.40. Lemaitre Vascular sees FY2022 revenue of $162-166 million, versus the consensus of $166.36 million.

For earnings history and earnings-related data on Lemaitre Vascular (LMAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15